| HOME >> MEDICINE >> TECHNOLOGY |
Russia enhances regulations to boost growth of the domestic pharma industry 87
India tackles growing healthcare expenditure by tightening price controls and increasing access to generic drugs 90
China's healthcare reforms will expand the domestic market but may create challenges for foreign companies 92
4. Generics and Biosimilars 95
The generics market 96
The biosimilars market 117
5. Recession and Recovery 131
Appendix
Pharmaceutical Key Trends 2010 DMHC2599
Largely insulated from the recession Pharma's key threat is the patent cliff 131
Biotech emerges from its funding crisis 138
6. Prescription Drug Market Outlook 146
Definitions – launch, core, expiry 146
Drivers and resistors for sales growth of the top 50 pharma companies out to 2014 146
7. Research and Development 164
Pharma continues to battle with R&D issues 164
Pharma's R&D cost-cutting exercise is only a short-term solution 168
Pharma's late-stage deal activity set to increase to help offset the patent cliff 170
Pharma's level of early-stage R&D collaboration intensifies 171
Outsourcing set to rise following initial cost-cutting exercises implemented during the economic downturn 173
Pharma sharpens its focus on secondary care indications through high value biologic therapies as the patent cliff looms 175
Personalized medicine and stem cell technology are key strategies in the commercialization of niche indications 183
Pharma embraces low cost late-stage lifecycle management strategies 187
8. Mergers and Acquisitions 192
M&A will remain a central strategy for Pharma 192
M&A deals to increase scale and cut costs 196
M&A deals to target high growth therapeutic markets 199
M&A deals to target high growth geographic marke
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |